Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Development and preparation of the EIC Accelerator application: First-in-human trial of CAR13(NAP)-T cells in patients with relapsed glioblastoma.
| Reference number | 2025-01488 |
| Coordinator | Elicera Therapeutics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2025 - October 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Last updated 16 June 2025
Reference number 2025-01488
